Enterovirus type 71 neutralizing antibodies in the serum of macaque monkeys immunized with EV71 virus-like particles

Area of Science:

• Virology
• Immunology
• Vaccine Development

Background:

• Enterovirus type 71 (EV71) is a significant cause of severe illness and mortality in young children.
• Current therapeutic and preventative options for EV71 infection are limited.
• The development of an effective EV71 vaccine is crucial to mitigate disease burden.

Purpose of the Study:

• To evaluate the immunogenicity of a novel Enterovirus type 71 (EV71) vaccine candidate based on virus-like particles (VLPs).
• To assess the humoral and cellular immune responses elicited by the VLP-based EV71 vaccine in a non-human primate model.

Main Methods:

• Vaccination of macaque monkeys with an EV71 virus-like particle (VLP) vaccine adjuvanted with alum.
• Measurement of EV71-specific antibodies, neutralization titers, ELISPOT assays, and T cell responses.
• Comparison of immune responses to those generated by an inactivated EV71 vaccine.

Main Results:

• The VLP-based EV71 vaccine successfully induced specific humoral and cellular immune responses in vaccinated macaques.
• While neutralizing antibody titers were lower compared to an inactivated EV71 vaccine, the VLP vaccine generated a robust memory immune response.
• ELISPOT and T cell assays confirmed cellular immunity development.

Conclusions:

• The virus-like particle (VLP) based EV71 vaccine is a promising candidate for preventing EV71 infection.
• The VLP vaccine elicits both humoral and cellular immunity, including a crucial memory response.
• Further development of this VLP-based EV71 vaccine is warranted.